Search
News & Events
Screen ORIGINS study finds mobile devices a lifeline for families during lockdownsA study of ORIGINS families has revealed a positive aspect to the COVID pandemic, with families found to benefit from the extra time together during lockdowns and mobile devices proving useful for helping them stay in touch with extended family and friends and for activities such as online classes.
News & Events
DETECT Schools Program UnderwayThe DETECT Schools program is underway, with swabs taken at 13 of the participating schools across Western Australia. No asymptomatic COVID-19 has been detected to date.
News & Events
New research prepares for COVID-19 vaccine roll-outAs the world waits for a COVID-19 vaccine Perth researchers are getting one step ahead – embarking on a new study designed to prepare parents and government for a potential Australia-wide vaccination program.
News & Events
Antiviral drug shown to speed up COVID-19 recoveryAn international research collaboration, including The Kids Research Institute Australia infectious disease specialist Tobias Kollmann, has shown that the antiviral drug Interferon can speed up the recovery of COVID-19 patients.
News & Events
Home participation resource for children with disability and complex needsFor families with a child with disability, this involves many extra care duties especially if their child has high and complex needs.
Research
UV light and COVID-19Investigator: Nisali Gamage Project description We critically review new studies which are emerging that report findings related to the effects of UV
With the number of COVID-19 infections in Western Australia continuing to grow – including confirmed cases in children – The Kids Research Institute Australia understands that our community is growing increasingly worried.
Thanks to 30 years of support from the WA community, The Kids Research Institute Australia is home to some of the world’s best researchers.
Research save lives and contains the spread of COVID-19.
Research
Real world effectiveness of early ensitrelvir treatment in patients with SARS-CoV-2, a retrospective case seriesEnsitrelvir, a 3C-like protease inhibitor, received emergency approval in Japan in November 2022 for treating non-hospitalized patients with mild-to-moderate COVID-19. However, confirmation of its real-world clinical effectiveness is limited.